Investigating how a specific protein affects inflammation during sepsis
How Tetraspanins Regulate Sepsis
This study is looking at how a protein called CD82 affects the body's response to sepsis, especially how it influences blood vessel behavior and immune cell activity, with the hope of finding new ways to help people who are dealing with this serious condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-10654676 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of tetraspanin CD82 proteins in the inflammatory responses associated with sepsis. It aims to uncover the mechanisms by which CD82 influences vascular leakage, leukocyte recruitment, and the release of cytokines, which are critical factors in the progression of sepsis. The study will involve assessing how CD82 affects the stability of endothelial cells and their interactions during inflammatory events. By exploring these cellular processes, the research seeks to provide insights that could lead to new therapeutic strategies for managing sepsis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of or currently experiencing sepsis, particularly those with underlying conditions that may exacerbate their inflammatory responses.
Not a fit: Patients who are not at risk for sepsis or those with conditions unrelated to inflammatory responses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for sepsis, potentially reducing mortality rates associated with this severe condition.
How similar studies have performed: Other research has shown promising results in understanding the role of cell adhesion molecules in inflammatory responses, suggesting that this approach could yield valuable insights.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Zhang, Xin a — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Zhang, Xin a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.